Fiona H. Marshall, President of Biomedical Research at Novartis, expressed her excitement, stating, "We are entering into this collaboration with Isomorphic Labs to leverage cutting-edge AI technologies and accelerate the delivery of innovative medicines to address unmet patient needs. Our shared vision is to expedite the discovery and development of novel small molecule therapeutics through the application of advanced AI models."

The collaboration builds on Novartis's ongoing efforts to develop AI tools and platforms that have the potential to enhance various aspects of drug development. By combining Isomorphic's predictive and generative AI modeling capabilities with massive computing power and Novartis's deep expertise in disease areas and medicinal chemistry, the partnership aims to unlock new possibilities in AI-driven drug discovery.

"At Novartis, we have great confidence that this collaboration with Isomorphic will help us accelerate the discovery and development of new medicines," added Fiona H. Marshall.

The collaboration will focus on utilizing Isomorphic's state-of-the-art AI technologies to generate actionable insights that aid decision-making in drug development. The synergy between Isomorphic's cutting-edge capabilities and Novartis's expertise promises to create a powerful platform for advancing the field of AI-driven drug discovery.

As the pharmaceutical industry continues to evolve, Novartis remains at the forefront of innovation, committed to delivering breakthrough therapies for patients worldwide. This strategic partnership with Isomorphic Labs represents a pivotal moment in the pursuit of accelerating drug discovery through the integration of advanced AI technologies.